[go: up one dir, main page]

TW200833372A - Use of (meth)acrylate copolymers in delayed-release pharmaceutical forms for decreasing the influence of ethanol on the release of active compound - Google Patents

Use of (meth)acrylate copolymers in delayed-release pharmaceutical forms for decreasing the influence of ethanol on the release of active compound

Info

Publication number
TW200833372A
TW200833372A TW96139674A TW96139674A TW200833372A TW 200833372 A TW200833372 A TW 200833372A TW 96139674 A TW96139674 A TW 96139674A TW 96139674 A TW96139674 A TW 96139674A TW 200833372 A TW200833372 A TW 200833372A
Authority
TW
Taiwan
Prior art keywords
release
active compound
meth
decreasing
influence
Prior art date
Application number
TW96139674A
Other languages
Chinese (zh)
Inventor
Hans-Ulrich Petereit
Brigitte Skalsky
Diego Gallardo
Manfred Assmus
Andreas Gryczke
Wolfgang Weisbrod
Felix Hofmann
Hans Baer
Original Assignee
Evonik Roehm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Roehm Gmbh filed Critical Evonik Roehm Gmbh
Publication of TW200833372A publication Critical patent/TW200833372A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to the use of gastric juice-insoluble (meth)acrylate copolymers in oral delayed-release pharmaceutical forms as a matrix-forming agent for the active compound contained for decreasing the effect of the acceleration or slowing of the release of active compound as a result of the influence of ethanol under in-vitro conditions.
TW96139674A 2006-10-26 2007-10-23 Use of (meth)acrylate copolymers in delayed-release pharmaceutical forms for decreasing the influence of ethanol on the release of active compound TW200833372A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE200610051020 DE102006051020A1 (en) 2006-10-26 2006-10-26 Use of (meth) acrylate copolymers in sustained release dosage forms to reduce the effect of ethanol on drug release

Publications (1)

Publication Number Publication Date
TW200833372A true TW200833372A (en) 2008-08-16

Family

ID=38521102

Family Applications (1)

Application Number Title Priority Date Filing Date
TW96139674A TW200833372A (en) 2006-10-26 2007-10-23 Use of (meth)acrylate copolymers in delayed-release pharmaceutical forms for decreasing the influence of ethanol on the release of active compound

Country Status (3)

Country Link
DE (1) DE102006051020A1 (en)
TW (1) TW200833372A (en)
WO (1) WO2008049657A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2187873B1 (en) 2007-08-13 2018-07-25 Abuse Deterrent Pharmaceutical Llc Abuse resistant drugs, method of use and method of making
PL2326313T3 (en) 2008-09-24 2015-08-31 Evonik Roehm Gmbh Ph-dependent controlled release pharmaceutical composition for non-opioids with resistance against the influence of ethanol
BRPI0823096B8 (en) 2008-09-24 2022-07-05 Evonik Roehm Gmbh pharmaceutical composition of a ph-dependent, controlled-release opioid with resistance against the influence of ethanol, process for its preparation, and its use
CN104984343B (en) * 2008-09-24 2019-04-02 赢创罗姆有限公司 The pharmaceutical composition of the dependent controlled release of pH for the non-opium drug that ethanol tolerant influences
US9730899B2 (en) * 2009-03-18 2017-08-15 Evonik Roehm Gmbh Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising neutral vinyl polymers and excipients
CN105287434A (en) * 2009-03-18 2016-02-03 赢创罗姆有限公司 Ethanol influence-resistant controlled-release medicine composition adopting coating containing neutral vinyl polymers and excipients
BRPI0924427A2 (en) * 2009-03-18 2016-01-26 Evonik Roehm Gmbh controlled release pharmaceutical composition, its preparation process and its use
ES2642788T3 (en) * 2010-05-10 2017-11-20 Euro-Celtique S.A. Manufacture of granules without active substance and tablets comprising the same
JP5840201B2 (en) 2010-05-10 2016-01-06 ユーロ−セルティーク エス．エイ． Combination of granules loaded with active agent and additional active agent
NZ700732A (en) 2010-05-10 2015-08-28 Euro Celtique Sa Pharmaceutical compositions comprising hydromorphone and naloxone
HUE033117T2 (en) 2011-06-17 2017-11-28 Evonik Roehm Gmbh Coating composition suitable for pharmaceutical or nutraceutical dosage forms
SI2720682T1 (en) 2011-06-17 2017-05-31 Evonik Roehm Gmbh Coating composition suitable for pharmaceutical or nutraceutical dosage forms
KR101902602B1 (en) 2011-06-17 2018-09-28 에보니크 룀 게엠베하 Gastric resistant pharmaceutical or nutraceutical composition with resistance against the influence of ethanol
US10420726B2 (en) 2013-03-15 2019-09-24 Inspirion Delivery Sciences, Llc Abuse deterrent compositions and methods of use
EP3068397A1 (en) 2013-11-13 2016-09-21 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
JP2022524458A (en) 2019-03-11 2022-05-02 エボニック オペレーションズ ゲーエムベーハー Dosage form containing polymer matrix

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4152414A (en) * 1978-08-18 1979-05-01 Iowa State University Research Foundation, Inc. Combination vaccine for swine dysentery and method of use
GB8519310D0 (en) * 1985-07-31 1985-09-04 Zyma Sa Granular active substances
US6391338B1 (en) * 1995-09-07 2002-05-21 Biovail Technologies Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
EP1301177A2 (en) * 2000-07-10 2003-04-16 Therics, Inc. Method and materials for controlling migration of binder liquid in a powder
DE10058771A1 (en) * 2000-11-27 2002-06-06 Falk Pharma Gmbh Coacervation process for the production of delayed-release drugs
HRP20020124A2 (en) * 2002-02-11 2003-10-31 Pliva D D Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
FI1765303T4 (en) * 2004-07-01 2023-01-31 Oral tablet safeguarded against abuse
EP1771160A2 (en) * 2005-01-28 2007-04-11 Euroceltique S.A. Alcohol resistant dosage forms
US20060193911A1 (en) * 2005-02-28 2006-08-31 Penwest Pharmaceuticals Co., Controlled release venlafaxine formulations
PL116330U1 (en) * 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
JP2009523833A (en) * 2006-01-21 2009-06-25 アボット ゲーエムベーハー ウント カンパニー カーゲー Formulations and methods for drug delivery
CA2671200A1 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophilic abuse deterrent delivery system

Also Published As

Publication number Publication date
WO2008049657A3 (en) 2008-10-30
DE102006051020A1 (en) 2008-04-30
WO2008049657A2 (en) 2008-05-02

Similar Documents

Publication Publication Date Title
TW200833372A (en) Use of (meth)acrylate copolymers in delayed-release pharmaceutical forms for decreasing the influence of ethanol on the release of active compound
PL1906939T3 (en) Use of a partially neutralized, anionic (meth)acrylate copolymer as a coating for the production of a medicament releasing active substance at reduced ph values
WO2006084164A3 (en) Gastric retention and controlled release delivery system
WO2007103200A3 (en) Oral controlled release formulation for sedative and hypnotic agents
PL2457562T3 (en) Zero-order modified release solid dosage forms
WO2011101866A3 (en) Gastric retention formulation containing baclofen
IL183357A0 (en) Oral medicament for the modified release of at least one active principle, in multimicrocapsule form
TR201902010T4 (en) Delivery device for oral administration of an agent.
CO6440564A2 (en) PHARMACEUTICAL COMPOSITIONS OF IMMEDIATE RELEASE THAT INCLUDE OXYCODONE AND NALOXONE
UA92641C2 (en) Pharmaceutical composition comprising amlodipine and losartan
MY148496A (en) Dpp iv inhibitor formulations
ZA200810164B (en) Sustained release pharmaceutical dosage form containing phenylphrine
WO2008022974A3 (en) Anti-diabetes composition containing chicoric acid and/or one of the metabolites thereof
TW200806282A (en) Solid dosage formulations
BRPI0817275A2 (en) Pharmaceutical combination of aliskiren and valsartan
IL201465A0 (en) Self-precipitating pharmaceutical formulations for the modified release of active principle
WO2009068708A3 (en) Pharmaceutical composition with prolonged release of somatostatin or an analogue thereof
NZ592927A (en) PHOSPHODIESTERASE TYPE III (PDE III) INHIBITORS OR CA2+-SENSITIZING AGENTS such as pimobendan FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
EP2384746A3 (en) Dual release oral tablet compositions of dexlansoprazole
ZA200901083B (en) Modified release pharmaceutical composition of bupropion hydrochloride
WO2008035229A3 (en) Compositions and methods for ph targeted drug delivery
WO2007110765A3 (en) Processes for the preparation of octreotide
WO2008070495A3 (en) Short term slow release drug delivery system
WO2008060546A3 (en) Oral formulations
WO2006109344A3 (en) Composition to be used for the treatment of parodontal pathologies